Dr. Sandip Ganguly
Senior Consultant
16 years of experienceMedical Oncologists
MBBS, MD, DM
Apollo Gleneagles Medical Centre, Kolkata
Book an AppointmentAbout Dr. Sandip Ganguly
Dr. Sandip Ganguly is a well?recognized Medical Oncologist with more than 15 years of professional experience. He focuses on treating breast cancer, cervical cancer, anal cancer, lung cancer, gastrointestinal cancer, thoracic cancer, gynecological cancer, etc. He earned his MBBS and MD in General Medicine from Kasturba Medical Coll., Mangalore, in 2008 and 2011. Later, in 2015, he specialized in cancer treatment by completing a DM in Medical Oncology from the Kidwai Memorial Inst. of Oncology. He is deeply dedicated to patient care and actively participates in global clinical trials and research initiatives. Dr. Ganguly has numerous publications in esteemed medical journals and advocates passionately for patient assistance programs to ensure optimal cancer treatment outcomes.Education
MBBS - Kasturba Medical Coll., Mangalore - 2008 MD - Kasturba Medical Coll., Mangalore - 2011 DM - Medical Oncology- Kidwai Memorial Inst. of Oncology - 2015Past Experience
Consultant Medical Oncologist Tata Medical Center - 2023 Resident, Medical Oncology Kidwai Memorial Inst. Of Oncology - 2015 Senior Resident Kasturba Medical Coll., Mangalore - 2012Paper Published
He has published over 123 articles. Some of them are: Real-world study of safety and efficacy of erlotinib as second line and beyond in ALK-rearranged advanced non-small cell lung cancer patients in India – a multicentre chart review study (ROSELAND) Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study. Canakinumab Versus Placebo in Combination With First-Line Pembrolizumab Plus Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Results From the CANOPY-1 Trial LBA11 Amivantamab plus chemotherapy vs. chemotherapy among Asian patients with EGFR-mutant advanced NSCLC after progression on osimertinib: A MARIPOSA-2 subgroup analysis 287MO Real-world professional experience with maintenance PARP inhibitor plus minus bevacizumab in newly diagnosed advanced ovarian cancer with germline BRCA mutations or homologous recombination deficiency (HRD) positive Amivantamab plus chemotherapy with and without lapatinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study 272P Correlation of dihydropyrimidine dehydrogenase gene mutation with toxicity among gastrointestinal cancers (GI) taking 5-fluorouracil-based chemotherapy: professional experience from a tertiary cancer center in the eastern part of India 272P Correlation of dihydropyrimidine dehydrogenase gene mutation with toxicity among gastrointestinal cancers (GI) taking 5-fluorouracil-based chemotherapy: professional experience from a tertiary cancer center in the eastern part of India Pancreatic Adenocarcinoma with Primary Tumor Calcification and Calcified Liver Metastasis: Report of a Rare Case and Review of Literature Hypofractionated radiation therapy comparing a standard radiotherapy schedule (over three weeks) with a novel 1-week schedule in adjuvant breast cancer: An open-label randomized controlled study (HYPORT-Adjuvant) - Study protocol for a multicentre, randomized phase III trial
Area of Expertise
- Chemotherapy
- Endometrial Biopsy
- Fine Needle Aspiration
- Hormone Therapy
- Immunotherapy
- Microsurgical Tumor Removal